Syros Pharmaceuticals (NASDAQ:SYRS) – Equities research analysts at Oppenheimer issued their Q1 2018 EPS estimates for shares of Syros Pharmaceuticals in a report issued on Monday. Oppenheimer analyst L. Cann forecasts that the company will post earnings of ($0.17) per share for the quarter. Oppenheimer has a “Buy” rating and a $28.00 price objective on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.51) EPS, Q3 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.59) EPS, FY2018 earnings at ($1.81) EPS, FY2019 earnings at ($2.28) EPS, FY2020 earnings at ($1.19) EPS, FY2021 earnings at $1.49 EPS and FY2022 earnings at $3.22 EPS.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Monday, March 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.01).
SYRS has been the subject of a number of other research reports. HC Wainwright restated a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday. BidaskClub upgraded Syros Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Friday, January 5th. Wedbush restated an “outperform” rating and issued a $13.00 target price (up previously from $11.00) on shares of Syros Pharmaceuticals in a report on Tuesday. Finally, Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. Syros Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $21.13.
Shares of Syros Pharmaceuticals (NASDAQ SYRS) opened at $12.62 on Thursday. The stock has a market capitalization of $398.17 and a price-to-earnings ratio of -5.95. Syros Pharmaceuticals has a 1-year low of $6.30 and a 1-year high of $24.38.
Several large investors have recently made changes to their positions in the stock. Adalta Capital Management LLC purchased a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $111,000. Two Sigma Investments LP raised its holdings in shares of Syros Pharmaceuticals by 80.3% during the fourth quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after acquiring an additional 9,439 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $105,000. ARK Investment Management LLC raised its holdings in shares of Syros Pharmaceuticals by 519.7% during the fourth quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock worth $8,122,000 after acquiring an additional 700,058 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth $191,000. Institutional investors and hedge funds own 48.18% of the company’s stock.
In other news, Director Srinivas Akkaraju acquired 209,424 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was acquired at an average cost of $9.55 per share, for a total transaction of $1,999,999.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/03/17/syros-pharmaceuticals-forecasted-to-earn-q1-2018-earnings-of-0-17-per-share-syrs.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.